BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
France honors the victims of the Paris attacks' night of terror 10 years on - 2Grasping Wrongdoings and Crimes: A Correlation
- 3‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- 4Step by step instructions to Explore Assessment Ramifications of Disc Rates
- 5Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- National health ranking puts Georgia near bottom of list. Here's why
- Obamacare enrollment declines as US subsidies expire
- The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
- The Response Uncovered: Disentangling the Secrets of the Universe
- A hospital discharged a woman in labor. This lawmaker wants change.
- What is IDF's view on pontential long-term occupation of southern Lebanon?
- Top 5 Top of the line Books of the Year
- Easy to understand Tech: Cell phones for Old in 2024
